A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C

Inclusion Criteria: * Adult patients, 18 to 65 years of age inclusive * Documented chronic hepatitis C * Treatment-naïve (no prior exposure to Pegasys, Copegus, or experimental HCV therapy) or treatment-experienced with current standard of care (Pegasys and Copegus) but categorized as null-responder or patients with partial response, relapse or viral breakthrough during or following prior treatment * Serum HCV RNA \>/= 50,000 IU/mL at screening * HCV antibody positive at screening * HCV genotype 1 * Body mass index (BMI) 18-38 kg/m2 * In good health other than chronic HCV infection in the judgment of the principal investigators * Negative for hepatitis B and HIV infection Exclusion Criteria: * Pregnant or breastfeeding women * For treatment-naïve patients: any previous treatment for HCV infection * For treatment-experienced patients: previous treatment with an experimental therapy for HCV infection * Co-infection with HIV or hepatitis C virus (HBV) * History or evidence of decompensated liver disease * History or evidence of hepatocellular carcinoma * History of alcohol abuse and/or other drug addiction \</= 1 year prior to enrollment in the study * Poorly controlled diabetes mellitus * One or more additional known primary causes of liver disease other than hepatitis C * History of acute or chronic pancreatitis * Participation in an other clinical study of a new chemical entity within 30 days prior to study randomization